.Attributes Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Perspective calls for incorporation of patients with MASLD as well as dimension of liver outcomes in cardio-- kidney-- metabolic trials, when information advise mechanistically plausible benefits and also professional protection-- and summarizes factors to consider for test style and also regulative approval.